DEFA14A: Quoin Pharmaceuticals Ltd. Adjourns Special General Meeting Due to Lack of Quorum

Quoin Pharmaceuticals Ltd. adjourned its Special General Meeting on March 29, 2024, due to a lack of quorum and will reconvene on April 5, 2024.

Summary

• Quoin Pharmaceuticals Ltd. held a Special General Meeting of Shareholders on March 29, 2024.
• The meeting was adjourned without any business being conducted due to the absence of a quorum.
• The Special Meeting will reconvene on April 5, 2024, at 12:00 pm Eastern Time, at the offices of Blank Rome LLP in Philadelphia.
• The record date for shareholders entitled to vote remains February 23, 2024.
• Proxies previously submitted will be voted at the reconvened meeting unless properly revoked.
• Shareholders who have already submitted a proxy do not need to take any further action.
• No changes have been made to the record date or the proposal to be considered at the meeting.
• The company encourages shareholders to read the Proxy Statement and other proxy materials available on the SEC's website.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the announcement primarily conveys procedural information about the adjournment and rescheduling of a meeting. The lack of quorum is a minor negative, but the rescheduling addresses the issue.

Positives

• Shareholders who have already submitted a proxy do not need to take any further action, simplifying the process for them.

Negatives

• The initial Special General Meeting had to be adjourned due to a lack of quorum, indicating potential challenges in shareholder engagement or participation.

Risks

• The inability to achieve a quorum raises concerns about shareholder engagement and the potential for future difficulties in obtaining necessary approvals.
• Further adjournments could lead to increased costs and delays in implementing the proposed resolutions.

Future Outlook

The company will proceed with the Special General Meeting on April 5, 2024, and hopes to achieve a quorum to conduct the meeting's business.

Management Comments

• The Company strongly encourages all of its shareholders to read the Company's Proxy Statement and other proxy materials relating to the Special Meeting.

Industry Context

The adjournment of a shareholder meeting due to lack of quorum is not uncommon, particularly for companies with a dispersed shareholder base. It highlights the importance of effective shareholder communication and engagement strategies.

Stakeholder Impact

• Shareholders are impacted by the delay in the Special General Meeting.
• The company's management and advisors are impacted by the need to reschedule and reconvene the meeting.

Next Steps

• The Special General Meeting will reconvene on April 5, 2024.
• Shareholders are encouraged to review the proxy materials and vote.

Key Dates

Keywords

Special General Meeting, Quoin Pharmaceuticals, Adjournment, Quorum, Shareholders, Proxy Statement, Vote